Hjem › Endometriekreft › New Mexico
Kliniske studier for Endometriekreft i New Mexico
13 studier for Endometriekreft søker deltakere på steder i New Mexico.
Byer i New Mexico
Offisiell studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of New Mexico Cancer Center, Albuquerque
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- University of New Mexico Cancer Center, Albuquerque
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 2. okt. 2026 · NCT05950464Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of New Mexico Cancer Center, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 2. okt. 2026 · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of New Mexico Cancer Center, Albuquerque
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 28. sep. 2026 · NCT05112601DESTINY-PANTUMOUR04
- Research Site, Farmington
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Albuquerque
RekruttererFase 2
Alder 18 til 130 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05489211A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of New Mexico Comprehensive Cancer Center ( Site 6046), Albuquerque
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 17. sep. 2026 · NCT06952504A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Albuquerque
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT05123482Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 29. jul. 2026 · NCT07044336Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 292, Albuquerque
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 16. jul. 2026 · NCT06906341Uterine Preservation Via Lifestyle Transformation
- University of New Mexico, Albuquerque
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 20. jan. 2026 · NCT05903131Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- University of New Mexico, Albuquerque
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 11. des. 2025 · NCT06795009SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.